Ceperognastat
chemical compound
Ceperognastat (LY3372689) is a drug candidate molecule under investigation to treat Alzheimer's disease. It targets the enzyme O-GlcNAcase. Its result is to reduce formation of tau protein tangles.
A molecule containing radioactive fluorine was used with a PET scan to show that ceperognastat binds in the human brain.
Ceperognastat was discovered via a high-throughput screening campaign followed by further optimization.
Eli Lilly and Company is recruiting subjects for a clinical trial. Some hospitals in Australia: St Vincent's Hospital, Sydney
Hornsby Ku-Ring-Gai Hospital, The Prince Charles Hospital, The Queen Elizabeth Hospital, Adelaide, Box Hill Hospital, and Delmont Private Hospital are involved. Results of the trial were expected by June 2024. Primary completion of the study occurred on 9th July 2024, with full completion expected in August 2024. In an investor call, it was disclosed that ceperognastat missed the primary endpoint of improvement on the Integrated Alzheimer's Disease Rating Scale.
Begin with the source’s own compact description: “Ceperognastat” is chemical compound. The dossier treats that line as a proposition to test through Ceperognastat, chemical and compound, not as a finished interpretation.
Why this record matters
The phrase “chemical compound” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The date and method of observation matter as much as the stated conclusion, especially where classification or consensus has changed. The source revision retrieved here is dated Aug 11, 2026. The linked authority identifier is Q111357415. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2024.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Ceperognastat”, its source revision and the description used here.
- Expand the search: follow Ceperognastat primary sources, Ceperognastat archive and Ceperognastat research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Ceperognastat”?
- Has classification or technical consensus changed since the cited source?
- Is the terminology current, historical or disputed?
Search terms from this dossier
This entry incorporates text from “Ceperognastat” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.